Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome (Q42468073)

1 November 2017

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

1 November 2017

1 reference

1 reference

1 reference

0 references

Ciampelli M

1

1 reference

1 November 2017

Fulghesu AM

2

1 reference

1 November 2017

Cucinelli F

3

1 reference

1 November 2017

Pavone V

4

1 reference

1 November 2017

Ronsisvalle E

5

1 reference

1 November 2017

Guido M

6

1 reference

1 November 2017

Caruso A

7

1 reference

1 November 2017

Lanzone A

8

1 reference

1 November 2017

language of work or name

1 reference

1 February 1999

1 reference

1 November 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

1 November 2017

48

1 reference

1 November 2017

2

1 reference

1 November 2017

167-172

1 reference

Polycystic ovary syndrome

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Pathogenesis and treatment of polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Polycystic ovary syndrome: a changing perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Metabolic approaches to the subclassification of polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The impact of obesity on hormonal parameters in hirsute and nonhirsute women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990028-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0026-0495(99)90028-8

1 reference

release_hhzvja6uovcatja2d3ujndu26u

1 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hhzvja6uovcatja2d3ujndu26u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference